HomeApproved Therapies

Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Santhera Announces Approval in Hong Kong for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
|
Less than 1 min read
|
Updated:

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment.

Santhera Pharmaceuticals announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older.

Read More

- Follow Us -
DMDWarrioR Instagram
Author: Can Ekinci
Add DMDWarrior as a preferred Google source to see more of our trusted coverage.

Disclaimer: This article is for informational purposes only and does not provide medical advice. Patients and families should discuss treatment options and clinical trials with their healthcare professionals.

DMDWarrior Clinical Trials Hub now available in 10 languages, providing AI-assisted Duchenne clinical trial information worldwide.

Trending on DMDWarrioR- Duchenne News

Load more

Related Articles

Load more